• Max Peters, Metha Maenhout, Jochem R N van der Voort van Zyp, Marinus A Moerland, Maaike R Moman, Lotte M G Steuten, Marijke J H van Deursen, and Marco van Vulpen.
• Department of Radiation Oncology, University Medical Center Utrecht, The Netherlands. Electronic address: m.peters-10@umcutrecht.nl.
• Radiother Oncol. 2014 Jul 1; 112 (1): 77-82.

PurposeWhole-gland salvage for recurrent prostate cancer (PCa) shows high failure and toxicity rates. Early and adequate localization of recurrences enables focal salvage, thereby potentially improving functional outcomes, while maintaining cancer control.Materials And MethodsRetrospective analysis yielded 20 focal salvage I125 brachytherapy patients for locally recurrent PCa after primary radiotherapy. Tumor was defined by multiparametric MRI and correspondence with transrectal biopsies. Dose data were obtained intra-operatively. The tumor was prescribed ⩾144 Gy. Toxicity was scored by the Common Terminology Criteria for Adverse Events version 4 (CTCAE-4). Biochemical failure (BF) was defined using the Phoenix criteria (PSA-nadir + 2.0 ng/ml). Quality of life (QoL) was measured by SF-36 Health Survey and European Organization of Research and Treatment of Cancer (EORTC) C30+3 and PR25 questionnaires.ResultsWith a median follow-up of 36 months (range 10-45), six patients experienced BF, of which three had no initial response. Grade 3 genitourinary (GU) toxicity occurred in one patient (a urethral stricture). The five previously potent patients retained erectile function. QoL remained decreased with regard to urinary symptoms.ConclusionFocal salvage I125 brachytherapy showed one grade 3 GU toxicity in the 20 treated patients. Biochemical response and QoL were acceptable.Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

34 keywords...

hide…